Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01403506

Study of the Effect of N-acetyl Cysteine on the Renal Graft Function Biomarkers (IL18, NGAL)

Disorder Related to Renal Transplantation Clinical Trial

Official title:
Phase 3 Study of N-acetyl Cysteine as an Antioxidant and Glutathione Synthesis Inducer on Biomarkers of Delayed Renal Graft Function Including NGAL and IL-18

Clinical Trial Summary

The purpose of this study is to investigate the effect of (NAC) N-Acetyl Cysteine on biomarkers of Delayed Graft Function (DGF), including Neutrophil Gelatinase Associated Lipocalin (NGAL) and Intereleukin 18 (IL18).

Clinical Trial Description

Kidney transplantation is the best treatment for most patients with end stage renal failure, but limited numbers of suitable kidneys are available for transplantation. So preservation of graft is vital. This necessitates the studies and interventions to improve outcome of renal transplantation surgery.

Delayed Graft Function (DGF) or delay in performance of transplanted kidney means absence of acceptable function in the renal activity in postgrafting phase. DGF is a consequence of ischemic and reperfusion injuries (IRI), and oxygen free radicals have a main role in pathophysiology of DGF. In meta-analysis studies, it has been demonstrated that DGF has a correlation with long and short time graft survival. Despite great advances in the transplantation procedure, dysfunction prevalence has not decreased. Major causes of this problem are the lack of appropriate markers for early diagnosis of DGF and on the other hand lack of appropriate and effective interventions to controll DGF.

Studies have shown that N-Acetyl Cysteine (NAC) can induce GSH synthesis, scavenger of free radicals, and infusion of NAC had similar effects as glutathione.

This is a randomized clinical trial (RCT) on patients who have received kidney transplantation from living donors. Sixty transplanted patients will be randomized into 2 groups. The first group of patients will be treated with NAC 600mg 6 hr before transplantation and two doses of NAC 12 hours apart after transplantation in addition to standard treatment, and the second group will receive only standard antirejection treatment. For all patients entered the study, urinary concentrations of IL18 and NGAL will be measured in designated times. Risk factors of DGF will be compared in two groups and effectiveness of NAC in reducing DGF will be determined. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

  • Disorder Related to Renal Transplantation
Clinical Trial Details
NCT number NCT01403506
Study type Interventional
Source hahid Beheshti University of Medical Sciences
Contact Jamshid Salamzadeh, PhD
Phone 00982188662334
Email j.salamzadeh@yahoo.com
Status Recruiting
Phase Phase 3
Start date April 2011
Completion date November 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT02581436 - Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR N/A
Terminated NCT01561404 - Effect of the Inhibition of the Mammalian Target of Rapamycin on Metabolism and Exercise Phase 4
Recruiting NCT02849899 - Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period Phase 3
Not yet recruiting NCT01289301 - Studying the Effect of Changing Immunosuppression in Case of Polyoma BK Virus Infection of the Renal Transplant Phase 4
Completed NCT00905957 - Transversus Abdominis Plane Block For Renal Transplant Recipients N/A
Active, not recruiting NCT02843867 - Orientation of the Lymphocyte Response to the Occurrence of Atherosclerotic Complications After Kidney Transplantation
Active, not recruiting NCT02751099 - Bone and Cardiovascular Disease After Kidney Transplant
Completed NCT01646099 - Sun Protection of Kidney Transplant Recipients N/A
Completed NCT01744067 - The Effects of Omega-3 Fatty Acids in Renal Transplantation Phase 4
Active, not recruiting NCT03935958 - Curcumin in Kidney Transplant Recipients N/A
Recruiting NCT02513602 - Osseointegrated Dental Implants in Kidney Transplanted Patients N/A
Completed NCT01844713 - Evaluation of Sun Protection Education for Kidney Transplant Recipients N/A
Recruiting NCT01550445 - Steroid Withdrawal Immunosuppression After Renal Transplantation Phase 4
Completed NCT02540395 - Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation N/A
Completed NCT01195194 - Selection of Immunosuppression in Kidney Transplant Recipients Depending on Pre-transplant Donor-specific T-cell Reactivity. Phase 4
Completed NCT00724022 - Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation Phase 4
Terminated NCT00167661 - Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation Phase 1/Phase 2
Completed NCT03968588 - Standard- Versus Reduced-dose Tacrolimus Combined With Generic Mycophenolate Mofetil in De Novo Renal Transplantation Phase 4
Recruiting NCT02515643 - Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients N/A
Completed NCT00455013 - A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation Phase 2